MSKai Releases Innovative Lumbar Spine MRI Segmentation and Measurement Artificial Intelligence Technology

MSKai, a developer of Artificial Intelligence-based radiological assist software for the musculoskeletal system, announces the release of the company’s Lumbar Spine MRI segmentation and measurement algorithm in conjunction with submission of a United States Provisional Patent application for “Systems and Methods for Improving Patient Outcomes for Musculoskeletal Care.”

“Artificial Intelligence is rapidly integrating into healthcare,” said Adam Bruggeman, MD, chief medical officer of MSKai. “The ability to accurately and consistently identify and measure spine anatomy will lead to further efficiencies for patients and providers in the practice of spine surgery.”

The current software is a radiological assist system for the evaluation of Lumbar Spine pathologies providing spine care practicitioners the ability to identify, measure, and classify spinal anatomy and pathologies from a quantitative and qualitative standpoint within seconds. The distinctive machine learning algorithm provides anatomical segmentation, anatomical measurement, pathology classification, and range threshold alerts.

The initial validation for MSKai’s Lumbar Spine MRI segmentation and measurement is derived from 413 patient MRI studies. When comparing ground truth data from six independent medical and biomechanical professionals, the measurement accuracy and segmentation accuracy range from 76% to 90%, depending on the focus. The current segmentation and measurement algorithm continues to improve with consistency and sets the framework for the evolution of machine learning-based radiological assist systems being integrated into clinical practice.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy